EMERYVILLE, Calif., Feb. 5 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NTI(R)) , today announced it will release its second quarter 2008 financial results, for the quarter ended December 31, 2007, on February 8. The Company will host a conference call on February 11, 2008.
Hosting the call will be Paul E. Freiman, President and Chief Executive Officer, and Craig W. Carlson, Vice President and Chief Financial Officer. The details for the call are as follows:
http://investor.shareholder.com/ntii/events.cfm
About Neurobiological Technologies, Inc.
NTI is a specialty biopharmaceutical company with expertise in identifying and acquiring promising drug candidates and in designing and managing late-stage clinical trials for central nervous system conditions. The Company is currently developing Viprinex(TM) (ancrod), a novel reperfusion agent that is in pivotal Phase 3 trials for the treatment of acute ischemic stroke.
CONTACT: Investor Relations Counsel, Walter Kass of Cordon Partners, LLC,
+1-212-300-4708, for Neurobiological Technologies, Inc.
Web site: http://www.ntii.com//
